TriangleFOR PATIENTS · SOURCE READING
Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
For information about the treatments listed below, see the Treatment Option Overview section.
Source links and citations
The treatment of symptomatic or progressive chronic lymphocytic leukemia (CLL) may include the following:
Source links and citations
Watchful waiting.
Source links and citations
Targeted therapy with any of the following drugs:
Source links and citations
Targeted therapy with any of the following drugs:
A tyrosine kinase inhibitor (acalabrutinib, zanubrutinib, or ibrutinib).
Source links and citations
Targeted therapy with any of the following drugs:
Venetoclax with obinutuzumab or rituximab.
Source links and citations
Chemotherapy and rituximab.
Source links and citations
Immunotherapy (lenalidomide) with or without rituximab.
Source links and citations
A clinical trial of bone marrow or peripheral blood stem cell transplantation.
Source links and citations
All of these treatments may be used for patients being treated for the first time and those who have been treated before. Because these treatments have not been compared in studies, it is not possible to know if one treatment is better than another. The choice of treatment is made based on test results, the patient's age and general health, and the desire to minimize short-term and long-term side effects.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice